Ablatotech

Ablatotech is a visionary biotech firm founded by Dr. George Ekema, focused on disrupting traditional medicine by developing the DAPYTAP platform. This technology is positioned as a superior alternative to both vaccines and monoclonal antibody therapies, with the goal of making cutting-edge treatments globally accessible. The company has initiated clinical trials for its first candidates and is actively enrolling patients, signaling its transition from platform development to clinical validation.

DAPYTAP (Direct Antigen Presentation via Yeast) is a proprietary platform that uses yeast to present antigens directly to the immune system, aiming to create safer, more effective, and drastically cheaper alternatives to traditional vaccines and monoclonal antibody therapies.

Ablatotech competes with major vaccine (Pfizer, Moderna) and monoclonal antibody (Roche, AbbVie) developers. Its differentiation is based on a claimed combination of lower cost, simplified logistics, and a novel yeast-based mechanism, but it must prove clinical superiority to overcome entrenched standards of care.